Distribution of amyloidosis subtypes based on tissue biopsy site - Consecutive analysis of 729 patients at a single amyloidosis center in Japan
- PMID: 33112446
- DOI: 10.1111/pin.13041
Distribution of amyloidosis subtypes based on tissue biopsy site - Consecutive analysis of 729 patients at a single amyloidosis center in Japan
Abstract
This study was performed to elucidate the distribution of amyloidosis subtypes based on tissue biopsy site. Samples obtained from 729 consecutive patients with amyloidosis were analyzed by immunohistochemical staining (IHC) and supplemental mass spectrometry (MS). The correlations between the type of organs from which samples were obtained and amyloidosis subtypes were investigated retrospectively. Among the patients, 95.1% were diagnosed by IHC and 4.9% were diagnosed by MS. The distribution of amyloidosis subtypes was as follows: AL, 59.1%; ATTR, 32.9%; AA, 4.0%; AH, 1.4%; Aβ2M, 0.8%; and others, 0.9%. AL was the most common subtype in most organs, including the liver, lung, kidney, lower urinary tract, bone marrow, gastrointestinal tract, and skin/subcutaneous tissue. ATTR was the most common subtype in the heart, carpal tunnel, and peripheral nerves. AH was the second most common subtype in renal biopsy. Three or more amyloidosis subtypes were detected in each organ. In conclusion, AL was the most common subtype in most biopsy sites except the heart, carpal tunnel, and peripheral nerve, in which ATTR was more common. Because several types of amyloidogenic protein were detected in each organ, amyloid typing must be pursued, no matter the site from where biopsy was obtained.
Keywords: amyloidosis subtypes; biopsy; diagnosis; immunoglobulin heavy chain amyloidosis; immunoglobulin light chain amyloidosis; immunohistochemistry; mass spectrometry; transthyretin amyloidosis.
© 2020 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Similar articles
-
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution.Amyloid. 2022 Sep;29(3):156-164. doi: 10.1080/13506129.2022.2031963. Epub 2022 Feb 9. Amyloid. 2022. PMID: 35135386
-
Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland Biopsies.Am J Surg Pathol. 2015 Aug;39(8):1035-44. doi: 10.1097/PAS.0000000000000430. Am J Surg Pathol. 2015. PMID: 25828388
-
[Classification of cardiac amyloidosis: an immunohistochemical analysis].Zhonghua Bing Li Xue Za Zhi. 2018 Feb 8;47(2):105-109. doi: 10.3760/cma.j.issn.0529-5807.2018.02.005. Zhonghua Bing Li Xue Za Zhi. 2018. PMID: 29429161 Chinese.
-
The Ultrastructure of Tissue Damage by Amyloid Fibrils.Molecules. 2021 Jul 29;26(15):4611. doi: 10.3390/molecules26154611. Molecules. 2021. PMID: 34361762 Free PMC article. Review.
-
Cardiac Amyloidosis: Diagnosis and Treatment Strategies.Curr Oncol Rep. 2017 Jul;19(7):46. doi: 10.1007/s11912-017-0607-4. Curr Oncol Rep. 2017. PMID: 28528458 Review.
Cited by
-
Amyloid detection and typing yield of skin biopsy in systemic amyloidosis and polyneuropathy.Ann Clin Transl Neurol. 2023 Dec;10(12):2347-2359. doi: 10.1002/acn3.51924. Epub 2023 Oct 18. Ann Clin Transl Neurol. 2023. PMID: 37849451 Free PMC article.
-
Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review.BMC Musculoskelet Disord. 2023 Sep 22;24(1):751. doi: 10.1186/s12891-023-06853-5. BMC Musculoskelet Disord. 2023. PMID: 37740174 Free PMC article.
-
Long-term surgical results of trabeculectomy for secondary glaucoma in Val30Met hereditary transthyretin amyloidosis.Sci Rep. 2023 Aug 7;13(1):12755. doi: 10.1038/s41598-023-40029-4. Sci Rep. 2023. PMID: 37550352 Free PMC article.
-
Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry.J Clin Med. 2023 May 26;12(11):3684. doi: 10.3390/jcm12113684. J Clin Med. 2023. PMID: 37297878 Free PMC article.
-
Transthyretin Variant Amyloidosis with a TTR A97D (p.A117D) Mutation Manifesting Remarkable Asymmetric Neuropathy.Intern Med. 2023 Aug 1;62(15):2261-2266. doi: 10.2169/internalmedicine.0798-22. Epub 2022 Dec 21. Intern Med. 2023. PMID: 36543209 Free PMC article.
References
REFERENCES
-
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-96.
-
- Benson MD, Buxbaum JN, Eisenberg DS et al. Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25: 215-19.
-
- Girnius S, Seldin DC, Skinner M et al. Hepatic response after high- dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica 2009; 94: 1029-32.
-
- Jelinek T, Kryukova E, Kufova Z, Kryukov F, Hajek R. Proteasome inhibitors in AL amyloidosis: Focus on mechanism of action and clinical activity. Hematol Oncol 2017; 35: 408-19.
-
- Katoh N, Ueno A, Yoshida T et al. Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: A retrospective single-center study. Int J Hematol 2017; 105: 341-48.
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
